Imagine a company…
rethinking CNS
Doing Big
transforming the delivery of care
This is Sage

We are a clinical-stage biopharmaceutical company committed to discovering, developing and delivering novel medicines to transform the lives of patients with life-altering disorders of the central nervous system (CNS)

Learn More About Our Therapeutic Focus

News The latest from Sage

See All News

Press Releases

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Events

Piper Jaffray 30th Annual Healthcare Conference

In the news

See Sage CEO Jeff Jonas on CNBC’s Mad Money

Pipeline Advancing a robust CNS clinical portfolio

We seek to make a positive impact on the unmet treatment needs of patients by advancing product candidates from a robust development pipeline of potential CNS therapeutics.

GABA
Compound
Indication
Brexanolone
Postpartum Depression
SAGE-217
Major Depressive Disorder
SAGE-217
Postpartum Depression
SAGE-217
Insomnia
SAGE-217
Bipolar Depression
SAGE-324
Parkinson's Disease
SAGE-324
Essential Tremor
SAGE-324
Epileptiform Disorders
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Compound: Brexanolone
Indicator: Postpartum Depression
Compound: SAGE-217
Indicator: Major Depressive Disorder
Compound: SAGE-217
Indicator: Postpartum Depression
Compound: SAGE-217
Indicator: Insomnia
Compound: SAGE-217
Indicator: Bipolar Depression
Compound: SAGE-324
Indicator: Parkinson's Disease
Compound: SAGE-324
Indicator: Essential Tremor
Compound: SAGE-324
Indicator: Epileptiform Disorders
NMDA
Compound
Indication
SAGE-718
NMDA Hypofunction
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Compound: SAGE-718
Indicator: NMDA Hypofunction

Patients & Caregivers Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by CNS disorders.

Postpartum Depression

Major Depressive Disorder

Patient Advocacy Programs
See Our Resources for Patients

Healthcare Providers It’s an exciting time in neuroscience

At Sage, our goal is to originate meaningfully differentiated drug candidates. We aim to transform the practice of medicine and rethink how CNS disorders are treated.

Learn More About Our Approach

Clinical Trials A distinct approach to neuroscience drug development

Sage is committed to developing new medicines to treat life-altering CNS disorders.

Learn More About Our Ongoing Clinical Trials

Working@Sage Rethinking CNS to make life better for patients and their families

Sage is a place where unconventional thinking to solve problems with new ideas is welcome - and where unconventional thinkers can imagine what's possible and do big.

Experience Our Culture